LONDON (Reuters) -Investors who rushed out of Wall Street during a month of U.S. policy shocks that raised European growth ...

Coya Therapeutics sees success in early COYA-302 FTD trial, aims for Phase 2b in H2 2025 and ALS filing in Q2 2025. Read why ...

Litecoin (LTC), Bitcoin Cash (BCH), and Dogecoin (DOGE) experienced significant rallies today, as nine proof-of-work cryptocurrencies surged following Nvidia's announcement of a $5.5 billion ...

Investors who rushed out of Wall Street during a month of U.S. policy shocks that raised European growth risks are turning ...

Rezolute has done well to continue to advance its lead drug from its pipeline, ersodetug. Click here to see why RZLT stock is ...

Global wariness of Chinese solar and E.V. domination offers India an opening. The government is spending money to try to ...

with a quarter picking cash as their preferred asset. Emerging markets were the next most popular choice, despite the strong blows U.S. recessions can deal to developing nations. As Wall Street ...

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today reported its financial and operating results ...

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase ...

The CEO of Tether, Paolo Ardoino, unveiled the company’s new project, Tether (.)ai, at Consensus 2025. According to ...

The Proof of Capability program will provide businesses ... sparking fresh scrutiny of Berkshire’s leadership, cash buildup, and share valuation. We sell different types of products and services ...